Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,009 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard Chemotherapy Clear all
Terminated Phase 1Phase 2 Interventional

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

NCT02575391
View directory record Official record
Conditions
Esophagitis
Interventions
Whole Food Intervention
Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Not listed Not applicable Interventional

Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis

NCT03107468
View directory record Official record
Conditions
Spondylolisthesis, Lumbosacral Region
Interventions
Mokhuri intensive treatment, Non-surgical conventional standard treatment
Other
Lead sponsor
Kim Ki Ok
Other
Eligibility
19 Years to 78 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

NCT03064490
View directory record Official record
Conditions
Locally Advanced Esophageal and Gastric Cancers (EGC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

NCT03493425
View directory record Official record
Conditions
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
154
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02122185
View directory record Official record
Conditions
Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, placebo, Chemotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02101385
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Breast Cancer
Interventions
Genomically Directed Monotherapy, Observation/Standard Therapy
Drug · Other
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)

NCT05337618
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Full-band Electrocorticography, Treatment Algorithm
Diagnostic Test · Combination Product
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

NCT03177291
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
Interventions
Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Value of Technology to Transfer Discharge Information

NCT00101868
View directory record Official record
Conditions
Information Dissemination, Interprofessional Relations
Interventions
Discharge communication software, Usual care discharge process
Device · Other
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Contrast-Enhanced Ultrasound

NCT03473249
View directory record Official record
Conditions
Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
Interventions
Contrast-Enhanced Ultrasound using Lumason
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 4 Interventional

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

NCT00224068
View directory record Official record
Conditions
Anemia
Interventions
Sodium ferric gluconate, ferrous sulfate, standard of care
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
32
States / cities
Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties

NCT05095779
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
Coaching calls, Nicotine replacement therapy, Financial Incentives
Behavioral · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

NCT03248570
View directory record Official record
Conditions
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Interventions
Pembrolizumab, Chemotherapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 2, 2026, 4:23 AM EDT
Completed No phase listed Observational

Use of the MiCK Assay for Apoptosis in AML

NCT00286845
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Standard Chemotherapy
Drug
Lead sponsor
Pierian Biosciences
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 2, 2026, 4:23 AM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

NCT04310007
View directory record Official record
Conditions
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
611
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional

CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer

NCT02827370
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Behavioral Dietary Intervention
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 1 Interventional

Revumenib in Combination With 7+3 + Midostaurin in AML

NCT06313437
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Interventions
Revumenib, Midostaurin, Cytarabine, Daunorubicin
Drug
Lead sponsor
Richard Stone, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

NCT01505530
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LY2495655, Placebo, Standard of Care Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Dallas, Texas • The Woodlands, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 1 Interventional

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

NCT04464200
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
Interventions
19(T2)28z1xx CAR T cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Terminated Not applicable Interventional

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

NCT03941366
View directory record Official record
Conditions
Rectal Cancer
Interventions
Standard of care chemotherapy with the change for avoidance of extensive surgery
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

NCT02519712
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Induction Chemotherapy, G-PBSC Infusion
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 2, 2026, 4:23 AM EDT